Presenter Speech
James Gordon (Analysts)
Good afternoon. I'm James Gordon, JPMorgan European pharma biotech analyst. And it's my pleasure to introduce the Genmab presentation this afternoon. And we're
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,385.00 DKK | +0.04% |
|
-2.77% | -7.20% |
01-31 | Genmab and Pfizer receive positive opinion on Tidvak | FW |
01-24 | Goldman Sachs lowers target price for Genmab to DKK 2,066 (2,425), reiterates neutral - BN | FW |
Presenter Speech
James Gordon (Analysts)
Good afternoon. I'm James Gordon, JPMorgan European pharma biotech analyst. And it's my pleasure to introduce the Genmab presentation this afternoon. And we're
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe